Regarding all-cause mortality, SGLT-2 inhibitor treatment was shown not to affect the risk for all-cause death among subjects hospitalized with acute HF or recently decompensated HF (RR = 0.77, 95% CI; 0.59–1.01, I2 = 0%), as shown in Figure 2a. Here, SLC5A2 is linked to hydrops fetalis.